<html>
<head>
    <title>report_cimaglermin-060215.htm</title>
    <!--Licensed to: Acorda-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">UNITED STATES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">WASHINGTON, D.C. 20549</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">FORM&#160;8-K</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">CURRENT REPORT</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="FONT-SIZE: 10pt; DISPLAY: inline">Date of Report (Date of Earliest Event Reported):&#160;</font><font style="FONT-WEIGHT: bold; DISPLAY: inline">June 2, 2015</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Acorda Therapeutics,&#160;Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">(Exact name of registrant as specified in its charter)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Delaware</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">000-50513</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">13-3831168</font></div>
</td>
</tr><tr>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(State or other jurisdiction</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(Commission</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(I.R.S. Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">of incorporation)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">File Number)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td valign="middle" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">420 Saw Mill River Road, Ardsley, NY</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">10502</font></div>
</td>
</tr><tr>
<td valign="middle" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">(Zip Code)</font></div>
</td>
</tr><tr>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="27%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td colspan="5" valign="top" width="84%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">Registrant&#8217;s telephone number, including area code:&#160;&#160;<font style="FONT-WEIGHT: bold; DISPLAY: inline">(914) 347-4300</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Not Applicable</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">Former name or former address, if changed since last report</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="DISPLAY: inline" face="Wingdings">o</font>&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Item 8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">On June 2, 2015, Acorda Therapeutics, Inc. (the &#8220;Company&#8221;) <font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">announced that it has put a hold on a Phase 1b clinical trial of cimaglermin alfa based on the occurrence of a case of hepatotoxicity (liver injury) meeting Hy&#8217;s Law criteria (elevated ALT, AST and bilirubin).</font> </font>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><br>
</font></div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">There was also one case of hepatotoxicity meeting Hy&#8217;s Law criteria reported in the previous Phase 1 clinical trial of cimaglermin, which resolved within several days. The Company has ongoing non-clinical studies to investigate the pathological basis for liver interactions.</font></font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><br>
</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">The Company plans to review these and other data from the cimaglermin trials with the U.S. Food and Drug Administration (FDA). Following discussions with the FDA, the Company will provide an update on the cimaglermin program.</font></font></div>
</div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">Forward Looking Statements</font></font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">This filing includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the Civitas transaction and to successfully integrate Civitas' operations into our operations; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies.</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 36pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this filing are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this filing.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>
</div>

<br>
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">SIGNATURES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td align="left" valign="top" width="43%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="41%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; FONT-WEIGHT: bold; DISPLAY: inline">Acorda Therapeutics,&#160;Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="43%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="37%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="43%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline">June 2, 2015</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline">By:</font></div>
</td>
<td align="left" valign="top" width="37%" style="BORDER-BOTTOM: black 1pt solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; DISPLAY: inline">/s/ Michael Rogers</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="43%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline">Name: Michael Rogers</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="43%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; FONT-STYLE: italic; DISPLAY: inline">Title: Chief Financial Officer</font></div>
</td>
</tr></table>
</div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "report_cimaglermin-060215.htm", "description": "8-K", "secsgml_size_bytes": 28374}]
{"company-data": {"conformed-name": "ACORDA THERAPEUTICS INC", "cik": "0001008848", "assigned-sic": "2836", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-50513", "film-number": "15905440"}, "business-address": {"street1": "420 SAW MILL RIVER ROAD", "city": "ARDSLEY", "state": "NY", "zip": "10502", "phone": "914-347-4300"}, "mail-address": {"street1": "420 SAW MILL RIVER ROAD", "city": "ARDSLEY", "state": "NY", "zip": "10502"}}
report_cimaglermin-060215.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 2, 2015
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-50513
13-3831168
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
420 Saw Mill River Road, Ardsley, NY
10502
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(914) 347-4300
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01                      Other Events
On June 2, 2015, Acorda Therapeutics, Inc. (the "Company")
announced that it has put a hold on a Phase 1b clinical trial of cimaglermin alfa based on the occurrence of a case of hepatotoxicity (liver injury) meeting Hy's Law criteria (elevated ALT, AST and bilirubin).
There was also one case of hepatotoxicity meeting Hy's Law criteria reported in the previous Phase 1 clinical trial of cimaglermin, which resolved within several days. The Company has ongoing non-clinical studies to investigate the pathological basis for liver interactions.
The Company plans to review these and other data from the cimaglermin trials with the U.S. Food and Drug Administration (FDA). Following discussions with the FDA, the Company will provide an update on the cimaglermin program.
Forward Looking Statements
This filing includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the Civitas transaction and to successfully integrate Civitas' operations into our operations; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this filing are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Acorda Therapeutics, Inc.
June 2, 2015
By:
/s/ Michael Rogers
Name: Michael Rogers
Title: Chief Financial Officer